The latest from BioStock
» International specialist congress and upcoming milestones for Chordate Medical
» Carbiotix reports and looks ahead
» Toleranzia carries out GMP manufacturing of TOL2
» Market launch next for Moberg Pharma
» Dicot gets green light to start phase I study
Read BioStock's weekly newsletter for v.33 here.
Don't miss today's company presentation with the CEO Anna Ljung! Follow the presentation via the banner below.
Morning news
Enzymatica announces new study results with ColdZyme. Read more.
Invent Medics Continence support is now available in additional regions. Read more.
Iconovo strengthens patent protection. Read more.
Diagonal Bio carries out a directed new share issue and raises loans totaling SEK 4,4 million. Read more.
Vicore Pharma announces results of exploratory study with EndoPAT. Read more.
Brain+ invites you to an investor update. Read more.
Herantis Pharma doses first patient in phase Ia study. Read more.
Index Pharmaceuticals abstract awarded at UEGW. Read more.
Last day of trading in Bisergens warrant TO2. Read more.
Reports
Calmark Cantargia Diagonal Bio Egetis Isofol Medical Contigo Care Orthoma UsDsign Stayble Therapeutics SyntheticMR Therapeutics Ultimovacs
Communiqué
Invitation to report presentation
News since Monday lunch
Board members and CEO of OncoZenge departs. Read more. The company has postponed its quarterly report. Read more.
The merger between Peptonic and Pharmiva has been approved. Read more.
Results with Prostatype Genomics genetic test was published in The Prostate. Read more.
IRLAB updated about mesdopetam. Read more.
Corline Biomedicals customer in Europe has strengthened financing. Read more.
Aqua Bio Technology presented the outcome in the subsequent share offering. Read more.
Novo Nordisk has repurchased shares. Read more.
Nordnet has flagged up in Synact Pharma. Read more.
Avanza has flagged in.Read more.
Hamlet Pharma has changed its name to Hamlet BioPharma. Read more.
Last day of trading in Calmark Sweden's warrant TO 3 B Read more.
Penser has published analysis updates on Abliva, Medivir, Ascelia Pharma and Bio-Works Technologies.
Redeye has published analysis updates on Bioservo and Medivir.
This morning's price development
Winner: Diagonal Bio 30,5%, Monivent 18,9%, Aptahem 17%, Ascelia Pharma 13%, Immunovia 11,2%
Förlorare: Calmark -17,7%, AlphaHelix -15,5%, RLS Global -14,5%, Ectin Research 12,4%, Attana -11,6%
Index: OMSX30 2155 +0,72%, Healthcare +0,26%
More from BioStock
» Neola CEO sees exciting autumn ahead
» Moberg Pharma's CEO on the issue and launch of MOB-015
» This is how BrainCool wants to create interest in the stroke industry
» Elicera's potential in cancer therapy published in Nature Communications
» Arcede hopes to reach a larger market than current drugs